Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

The U.S. Food and Drug Administration (U.S. Food and Drug Administration) staff have raised concerns about the evidence supporting Moderna’s (Moderna) experimental flu vaccine mFlusiva ahead of a key advisory panel meeting in Washington. Regulators questioned the strength and completeness
Neumora Therapeutics has reported three consecutive Phase III failures for its major depressive disorder candidate navacaprant after KOASTAL-2 and KOASTAL-3 failed to meet primary and key secondary endpoints. The company confirmed it will discontinue development of the asset and reduce
Regulators and industry stakeholders are reassessing whether body weight alone is a sufficient endpoint for obesity therapies. In a recent Boehringer Ingelheim discussion, Brian Hilberdink highlighted a shift toward metabolic health as a more meaningful indicator of clinical benefit. The
In a feature published on June 16, 2026, BioSpace highlighted six real-world cases where drug development shifted from corporate strategy to deeply personal missions. The report shows how rare disease diagnoses within families of biotech leaders influenced company formation, clinical
Simcere Pharmaceutical Group has launched a research collaboration with Stanford Medicine to develop potential first-in-class therapies for idiopathic pulmonary fibrosis (IPF), a progressive and life-threatening lung disease. Under this agreement announced on June 15, 2026, Simcere Pharmaceutical Group funds early
Sigma Healthcare pulled back from its early-stage attempt to acquire UK pharmacy giant Boots after concluding that the deal does not align with its strategic and capital priorities. The Australian pharmaceutical wholesaler shifted its focus back to its domestic market,
Johnson & Johnson unveiled phase 3 findings at the European Hematology Association Congress 2026 in Stockholm, highlighting the growing impact of bispecific antibodies in multiple myeloma treatment. Results from the MonumenTAL-3 phase 3 study showed that Talvey combined with Darzalex
Eli Lilly has unveiled early clinical results from its Ajax Therapeutics acquisition at the European Hematology Association (EHA) 2026 meeting, showing strong activity of a next-generation JAK2 inhibitor in patients with myelofibrosis who had already failed prior therapies. The data
The U.S. Food and Drug Administration has expanded the indication of Tzield, developed by Sanofi SA, to include children and adolescents aged 8 to 17 who have recently been diagnosed with stage 3 type 1 diabetes. This update broadens the
Tensions between Amgen and the U.S. Food and Drug Administration have intensified after the regulator raised serious safety concerns regarding Amgen and pushed for its voluntary withdrawal from the market. The FDA pointed to emerging safety signals and post-marketing adverse